TG Therapeutics Stock Price, News & Analysis (NASDAQ:TGTX)

$8.25 0.00 (0.00 %)
(As of 12/15/2017 04:00 PM ET)
Previous Close$8.25
Today's Range$8.18 - $8.40
52-Week Range$4.10 - $15.35
Volume1.52 million shs
Average Volume1.23 million shs
Market Capitalization$582.88 million
P/E RatioN/A
Dividend YieldN/A
Beta1.24

About TG Therapeutics (NASDAQ:TGTX)

TG Therapeutics logoTG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes. The Company is also developing TGR-1202, an orally available Phosphoinositide 3-kinase (PI3K) delta inhibitor. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs focusing on developing interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and anti- programmed cell death ligand 1 (PD-L1) and anti- glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies.

Receive TGTX News and Ratings via Email

Sign-up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:TGTX
CUSIPN/A
Phone+1-212-5544484

Debt

Debt-to-Equity RatioN/A
Current Ratio4.94%
Quick Ratio4.94%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$150,000.00
Price / Sales3,885.75
Cash FlowN/A
Price / CashN/A
Book Value$0.66 per share
Price / Book12.50

Profitability

Trailing EPS($1.93)
Net Income$-78,250,000.00
Net Margins-73,217.77%
Return on Equity-151.21%
Return on Assets-116.84%

Miscellaneous

Employees64
Outstanding Shares70,650,000

TG Therapeutics (NASDAQ:TGTX) Frequently Asked Questions

What is TG Therapeutics' stock symbol?

TG Therapeutics trades on the NASDAQ under the ticker symbol "TGTX."

How were TG Therapeutics' earnings last quarter?

TG Therapeutics Inc (NASDAQ:TGTX) announced its quarterly earnings data on Wednesday, November, 8th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.43) by $0.05. The biopharmaceutical company had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.04 million. TG Therapeutics had a negative net margin of 73,217.77% and a negative return on equity of 151.21%. View TG Therapeutics' Earnings History.

Where is TG Therapeutics' stock going? Where will TG Therapeutics' stock price be in 2017?

9 analysts have issued twelve-month target prices for TG Therapeutics' shares. Their forecasts range from $21.50 to $33.00. On average, they anticipate TG Therapeutics' share price to reach $27.19 in the next twelve months. View Analyst Ratings for TG Therapeutics.

What are Wall Street analysts saying about TG Therapeutics stock?

Here are some recent quotes from research analysts about TG Therapeutics stock:

  • 1. According to Zacks Investment Research, "TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various B-cell proliferative disorders including lymphoma, leukemia, and auto-immune diseases. TG Therapeutics, Inc., formerly known as Manhattan Pharmaceuticals, Inc., is based in New York. " (8/12/2017)
  • 2. FBR & Co analysts commented, "On the morning of March 6, TG Therapeutics announced positive top-line data from its Phase III GENUINE study of TG-1101 (ublituximab) plus ibrutinib in patients with previously treated high-risk chronic lymphocytic leukemia (CLL). The study met its primary endpoint, with an overall response rate (ORR) of 80% in the combination of TG-1101 plus ibrutinib compared to ibrutinib alone in treated patients. The GENUINE Phase III study is a randomized, open-label multi-center trial that is being conducted to evaluate the safety and efficacy of TG-1101 plus ibrutinib compared to ibrutinib alone that has enrolled 126 adult patients with high-risk CLL across 160 clinical sites in the U.S. and Israel. In the study, high risk was defined as patients with one or more of the following: 17p deletion, 11q deletion, or p53 mutation. We believe the top-line data from the study are highly compelling and look forward to the full data set, which the company is targeting to present at a medical meeting in 1H17. The company plans to meet with the FDA to discuss the results and filing for accelerated approval in 2H17." (3/6/2017)

Are investors shorting TG Therapeutics?

TG Therapeutics saw a drop in short interest during the month of November. As of November 30th, there was short interest totalling 15,880,967 shares, a drop of 11.2% from the November 15th total of 17,893,222 shares. Based on an average trading volume of 1,400,762 shares, the short-interest ratio is currently 11.3 days. Currently, 28.2% of the shares of the stock are short sold.

Who are some of TG Therapeutics' key competitors?

Who are TG Therapeutics' key executives?

TG Therapeutics' management team includes the folowing people:

  • Michael S. Weiss, Executive Chairman of the Board, President, Chief Executive Officer (Age 51)
  • Sean A. Power CPA, Chief Financial Officer, Treasurer, Corporate Secretary (Age 35)
  • Laurence Neil Charney, Independent Director (Age 70)
  • Yann Echelard, Independent Director (Age 53)
  • Kenneth Hoberman, Independent Director (Age 52)
  • Daniel Hume, Independent Director (Age 51)
  • William J. Kennedy Ph.D., Independent Director (Age 71)

Who owns TG Therapeutics stock?

TG Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Columbus Circle Investors (2.23%), Jennison Associates LLC (1.81%), Artal Group S.A. (0.58%), JPMorgan Chase & Co. (0.52%), Schwab Charles Investment Management Inc. (0.34%) and Ameriprise Financial Inc. (0.26%). Company insiders that own TG Therapeutics stock include Laurence N Charney, Sean A Power and William James Kennedy. View Institutional Ownership Trends for TG Therapeutics.

Who sold TG Therapeutics stock? Who is selling TG Therapeutics stock?

TG Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Artal Group S.A., Ameriprise Financial Inc., Stoneridge Investment Partners LLC, Russell Investments Group Ltd., California State Teachers Retirement System and JPMorgan Chase & Co.. Company insiders that have sold TG Therapeutics company stock in the last year include Laurence N Charney, Sean A Power and William James Kennedy. View Insider Buying and Selling for TG Therapeutics.

Who bought TG Therapeutics stock? Who is buying TG Therapeutics stock?

TG Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Schwab Charles Investment Management Inc., Columbus Circle Investors, Hikari Power Ltd, Raymond James Financial Services Advisors Inc., Sectoral Asset Management Inc and Swiss National Bank. View Insider Buying and Selling for TG Therapeutics.

How do I buy TG Therapeutics stock?

Shares of TG Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is TG Therapeutics' stock price today?

One share of TG Therapeutics stock can currently be purchased for approximately $8.25.

How big of a company is TG Therapeutics?

TG Therapeutics has a market capitalization of $582.88 million and generates $150,000.00 in revenue each year. The biopharmaceutical company earns $-78,250,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis. TG Therapeutics employs 64 workers across the globe.

How can I contact TG Therapeutics?

TG Therapeutics' mailing address is 2 Gansevoort St Fl 9, NEW YORK, NY 10014-1667, United States. The biopharmaceutical company can be reached via phone at +1-212-5544484 or via email at [email protected]


MarketBeat Community Rating for TG Therapeutics (TGTX)

Community Ranking:  3.8 out of 5 (star star star)
Outperform Votes:  346 (Vote Outperform)
Underperform Votes:  113 (Vote Underperform)
Total Votes:  459
MarketBeat's community ratings are surveys of what our community members think about TG Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

TG Therapeutics (NASDAQ:TGTX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $25.90$26.34$24.84$24.84
Price Target Upside: 213.94% upside219.27% upside123.78% upside123.78% upside

TG Therapeutics (NASDAQ:TGTX) Consensus Price Target History

Price Target History for TG Therapeutics (NASDAQ:TGTX)

TG Therapeutics (NASDAQ:TGTX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/12/2017Raymond James FinancialReiterated RatingBuyLowView Rating Details
12/11/2017HC WainwrightReiterated RatingBuy$33.00HighView Rating Details
12/11/2017B. RileyReiterated RatingBuy$21.50HighView Rating Details
10/3/2017SunTrust BanksReiterated RatingBuy$28.00MediumView Rating Details
6/17/2017FBR & CoReiterated RatingBuyLowView Rating Details
6/5/2017Jefferies GroupReiterated RatingBuy$23.00MediumView Rating Details
3/8/2017Ladenburg Thalmann Financial ServicesSet Price TargetBuy$30.00LowView Rating Details
3/7/2017Langenberg & CompanyBoost Price TargetPositive$28.00 -> $30.00N/AView Rating Details
2/22/2017AegisInitiated CoverageBuy$26.00N/AView Rating Details
12/7/2016Roth CapitalSet Price TargetBuy$33.00N/AView Rating Details
10/6/2016Brean CapitalReiterated RatingBuy$28.00N/AView Rating Details
8/24/2016S&P Equity ResearchLower Price Target$7.15 -> $6.40N/AView Rating Details
(Data available from 12/16/2015 forward)

Earnings

TG Therapeutics (NASDAQ:TGTX) Earnings History and Estimates Chart

Earnings by Quarter for TG Therapeutics (NASDAQ:TGTX)

TG Therapeutics (NASDAQ TGTX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017Q3 2017($0.43)($0.48)$0.04 million$0.04 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.46)($0.45)$0.04 million$0.04 millionViewListenView Earnings Details
5/5/2017Q1 2017($0.42)($0.52)$0.04 million$0.04 millionViewN/AView Earnings Details
11/7/2016Q3($0.31)($0.50)$0.04 million$0.04 millionViewListenView Earnings Details
8/8/2016Q2($0.29)($0.33)$0.04 million$0.04 millionViewN/AView Earnings Details
5/10/2016Q1($0.36)($0.28)$0.04 million$0.04 millionViewListenView Earnings Details
3/7/2016Q4($0.32)($0.37)$38.10 million$38.10 millionViewN/AView Earnings Details
11/9/2015Q3($0.34)($0.28)$0.04 million$0.04 millionViewN/AView Earnings Details
8/10/2015Q215($0.32)($0.38)$0.22 million$0.04 millionViewListenView Earnings Details
5/4/2015Q115($0.33)($0.39)$0.04 million$0.04 millionViewN/AView Earnings Details
3/11/2015Q414($0.26)($0.48)$0.04 million$0.04 millionViewN/AView Earnings Details
11/10/2014Q214($0.32)($0.51)$0.04 million$0.04 millionViewN/AView Earnings Details
7/21/2014($0.28)($0.36)$0.04 million$0.04 millionViewN/AView Earnings Details
5/12/2014Q114($0.19)($0.25)$0.04 million$0.04 millionViewN/AView Earnings Details
3/5/2014Q413($0.18)($0.19)$40.00 million$38.10 millionViewN/AView Earnings Details
11/11/2013Q313($0.22)($0.62)$0.03 million$0.04 millionViewN/AView Earnings Details
8/1/2013Q213($0.16)($0.29)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

TG Therapeutics (NASDAQ:TGTX) Earnings Estimates

2017 EPS Consensus Estimate: ($1.79)
2018 EPS Consensus Estimate: ($1.97)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.48)($0.47)($0.48)
Q2 20173($0.45)($0.37)($0.41)
Q3 20173($0.50)($0.40)($0.45)
Q4 20173($0.46)($0.43)($0.45)
Q1 20181($0.48)($0.48)($0.48)
Q2 20181($0.48)($0.48)($0.48)
Q3 20181($0.50)($0.50)($0.50)
Q4 20181($0.51)($0.51)($0.51)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for TG Therapeutics (NASDAQ:TGTX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

TG Therapeutics (NASDAQ TGTX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 16.70%
Institutional Ownership Percentage: 50.45%
Insider Trades by Quarter for TG Therapeutics (NASDAQ:TGTX)
Insider Trades by Quarter for TG Therapeutics (NASDAQ:TGTX)

TG Therapeutics (NASDAQ TGTX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/19/2017Sean A PowerCFOSell59,976$11.09$665,133.84View SEC Filing  
4/11/2017William James KennedyDirectorSell8,548$10.27$87,787.96View SEC Filing  
4/4/2017Laurence N. CharneyDirectorSell7,000$11.17$78,190.00View SEC Filing  
1/4/2017Sean A. PowerCFOSell8,816$4.55$40,112.80View SEC Filing  
4/18/2016Sean A PowerCFOSell10,000$10.12$101,200.00View SEC Filing  
1/5/2016Sean A PowerCFOSell22,790$11.21$255,475.90View SEC Filing  
7/8/2015William James KennedyDirectorSell17,000$17.08$290,360.00View SEC Filing  
7/1/2015Sean A PowerCFOSell50,054$16.46$823,888.84View SEC Filing  
4/2/2015Sean A PowerCFOSell23,800$15.50$368,900.00View SEC Filing  
1/7/2015Sean A PowerCFOSell66,401$16.40$1,088,976.40View SEC Filing  
1/5/2015Sean A PowerCFOSell54,057$16.40$886,534.80View SEC Filing  
12/16/2014Michael S WeissMajor ShareholderSell210,618$16.44$3,462,559.92View SEC Filing  
12/16/2014Sean A PowerCFOSell38,041$16.44$625,394.04View SEC Filing  
12/11/2013Michael Weissmajor shareholderBuy10,000$3.43$34,300.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

TG Therapeutics (NASDAQ TGTX) News Headlines

Source:
DateHeadline
Zacks: Brokerages Anticipate TG Therapeutics Inc (TGTX) to Post -$0.46 EPSZacks: Brokerages Anticipate TG Therapeutics Inc (TGTX) to Post -$0.46 EPS
www.americanbankingnews.com - December 16 at 5:14 AM
TG Therapeutics: Oncology Concern Looks Like Solid Bet In 2018 - Seeking AlphaTG Therapeutics: Oncology Concern Looks Like Solid Bet In 2018 - Seeking Alpha
seekingalpha.com - December 15 at 3:33 PM
TG Therapeutics: Expecting A 2018 Cancer Star - Seeking AlphaTG Therapeutics: Expecting A 2018 Cancer Star - Seeking Alpha
seekingalpha.com - December 15 at 3:33 PM
TG Therapeutics, Inc. (TGTX) Short Interest UpdateTG Therapeutics, Inc. (TGTX) Short Interest Update
www.americanbankingnews.com - December 14 at 4:10 AM
TG Therapeutics (TGTX) Earns "Buy" Rating from Raymond James FinancialTG Therapeutics (TGTX) Earns "Buy" Rating from Raymond James Financial
www.americanbankingnews.com - December 12 at 6:34 PM
TG Therapeutics (TGTX) Stock Rating Reaffirmed by B. RileyTG Therapeutics (TGTX) Stock Rating Reaffirmed by B. Riley
www.americanbankingnews.com - December 11 at 5:46 PM
TG Therapeutics (TGTX) Buy Rating Reiterated at HC WainwrightTG Therapeutics' (TGTX) Buy Rating Reiterated at HC Wainwright
www.americanbankingnews.com - December 11 at 5:08 PM
TG Therapeutics Inc (TGTX): Does -30.2% EPS Decline Lately Make It An Underperformer?TG Therapeutics Inc (TGTX): Does -30.2% EPS Decline Lately Make It An Underperformer?
finance.yahoo.com - December 11 at 3:28 PM
ETFs with exposure to TG Therapeutics, Inc. : December 11, 2017ETFs with exposure to TG Therapeutics, Inc. : December 11, 2017
finance.yahoo.com - December 11 at 3:28 PM
TG Therapeutics, Inc. Announces Preclinical & Clinical Data Presentations at the 59th American Society of Hematology Annual MeetingTG Therapeutics, Inc. Announces Preclinical & Clinical Data Presentations at the 59th American Society of Hematology Annual Meeting
feeds.benzinga.com - December 11 at 8:03 AM
TG Therapeutics (TGTX) Recaps Data Presentations at ASH Meeting - StreetInsider.comTG Therapeutics (TGTX) Recaps Data Presentations at ASH Meeting - StreetInsider.com
www.streetinsider.com - December 10 at 9:32 AM
TG Therapeutics, Inc. (TGTX) Receives Consensus Recommendation of "Buy" from BrokeragesTG Therapeutics, Inc. (TGTX) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - December 7 at 5:54 PM
TG Therapeutics (TGTX) Receives New Coverage from Analysts at B. RileyTG Therapeutics (TGTX) Receives New Coverage from Analysts at B. Riley
www.americanbankingnews.com - December 1 at 7:49 AM
ETFs with exposure to TG Therapeutics, Inc. : November 30, 2017ETFs with exposure to TG Therapeutics, Inc. : November 30, 2017
finance.yahoo.com - November 30 at 3:29 PM
TG Therapeutics, Inc. :TGTX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017TG Therapeutics, Inc. :TGTX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
finance.yahoo.com - November 29 at 9:48 AM
TG Therapeutics, Inc. (TGTX) Expected to Post Quarterly Sales of $40,000.00TG Therapeutics, Inc. (TGTX) Expected to Post Quarterly Sales of $40,000.00
www.americanbankingnews.com - November 29 at 2:08 AM
-$0.47 EPS Expected for TG Therapeutics, Inc. (TGTX) This Quarter-$0.47 EPS Expected for TG Therapeutics, Inc. (TGTX) This Quarter
www.americanbankingnews.com - November 27 at 11:20 PM
TG Therapeutics Announces Initiation of National Cancer Institute/SWOG-Sponsored Randomized Phase II Trial in Follicular LymphomaTG Therapeutics Announces Initiation of National Cancer Institute/SWOG-Sponsored Randomized Phase II Trial in Follicular Lymphoma
finance.yahoo.com - November 27 at 4:02 PM
Today’s Research Reports on Trending Tickers: MannKind Corporation and TG TherapeuticsToday’s Research Reports on Trending Tickers: MannKind Corporation and TG Therapeutics
finance.yahoo.com - November 22 at 9:58 AM
PAREXEL International (PRXL) vs. TG Therapeutics (TGTX) Head-To-Head ReviewPAREXEL International (PRXL) vs. TG Therapeutics (TGTX) Head-To-Head Review
www.americanbankingnews.com - November 14 at 1:36 PM
TG Therapeutics, Inc. (TGTX) Given "Buy" Rating at HC WainwrightTG Therapeutics, Inc. (TGTX) Given "Buy" Rating at HC Wainwright
www.americanbankingnews.com - November 14 at 8:46 AM
TG Therapeutics, Inc. Expected to Post FY2017 Earnings of ($1.77) Per Share (TGTX)TG Therapeutics, Inc. Expected to Post FY2017 Earnings of ($1.77) Per Share (TGTX)
www.americanbankingnews.com - November 13 at 1:50 AM
TG Therapeutics, Inc. (TGTX) to Post FY2017 Earnings of ($1.91) Per Share, SunTrust Banks ForecastsTG Therapeutics, Inc. (TGTX) to Post FY2017 Earnings of ($1.91) Per Share, SunTrust Banks Forecasts
www.americanbankingnews.com - November 13 at 1:49 AM
TG Therapeutics, Inc. (TGTX) Receives Average Rating of "Buy" from BrokeragesTG Therapeutics, Inc. (TGTX) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - November 12 at 8:13 PM
TG Therapeutics, Inc. (TGTX) Receives Average Rating of "Buy" from BrokeragesTG Therapeutics, Inc. (TGTX) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - November 12 at 8:13 PM
TG Therapeutics (TGTX) CEO Michael Weiss on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaTG Therapeutics' (TGTX) CEO Michael Weiss on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 12 at 8:22 AM
TG Therapeutics, Inc. (TGTX) Releases  Earnings Results, Misses Estimates By $0.05 EPSTG Therapeutics, Inc. (TGTX) Releases Earnings Results, Misses Estimates By $0.05 EPS
www.americanbankingnews.com - November 9 at 7:46 PM
TG Therapeutics (TGTX) PT Raised to $36 at SunTrust Robinson Humphrey; Catalyst Rich 6-18 Months - StreetInsider.comTG Therapeutics (TGTX) PT Raised to $36 at SunTrust Robinson Humphrey; Catalyst Rich 6-18 Months - StreetInsider.com
www.streetinsider.com - November 9 at 3:30 PM
Zacks: Brokerages Anticipate TG Therapeutics, Inc. (TGTX) Will Post Earnings of -$0.48 Per ShareZacks: Brokerages Anticipate TG Therapeutics, Inc. (TGTX) Will Post Earnings of -$0.48 Per Share
www.americanbankingnews.com - November 9 at 10:31 AM
TG Therapeutics, Inc. Provides Business Update and Reports Third ... - GlobeNewswire (press release)TG Therapeutics, Inc. Provides Business Update and Reports Third ... - GlobeNewswire (press release)
globenewswire.com - November 9 at 8:04 AM
TG Therapeutics, Inc. Provides Business Update and Reports Third Quarter 2017 Financial ResultsTG Therapeutics, Inc. Provides Business Update and Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 9 at 8:04 AM
TG Therapeutics reports 3Q lossTG Therapeutics reports 3Q loss
finance.yahoo.com - November 9 at 8:04 AM
Edited Transcript of TGTX earnings conference call or presentation 8-Nov-17 1:30pm GMTEdited Transcript of TGTX earnings conference call or presentation 8-Nov-17 1:30pm GMT
finance.yahoo.com - November 9 at 8:04 AM
Financial Analysis: TG Therapeutics (TGTX) vs. Its PeersFinancial Analysis: TG Therapeutics (TGTX) vs. Its Peers
www.americanbankingnews.com - November 7 at 2:06 PM
TG Therapeutics, Inc. to Host Conference Call on Third Quarter 2017 Financial Results and Business Update - GlobeNewswire (press release)TG Therapeutics, Inc. to Host Conference Call on Third Quarter 2017 Financial Results and Business Update - GlobeNewswire (press release)
globenewswire.com - November 6 at 8:08 AM
TG Therapeutics, Inc. to Host Conference Call on Third Quarter 2017 Financial Results and Business UpdateTG Therapeutics, Inc. to Host Conference Call on Third Quarter 2017 Financial Results and Business Update
finance.yahoo.com - November 6 at 8:08 AM
TG Therapeutics (TGTX) Presents On 2017 Post ECTRIMS - ACTRIMS - SlideshowTG Therapeutics (TGTX) Presents On 2017 Post ECTRIMS - ACTRIMS - Slideshow
seekingalpha.com - November 5 at 7:05 AM
TG Therapeutics, Inc. Announces Data Presentations at the Upcoming 59th American Society of Hematology Annual ... - GlobeNewswire (press release)TG Therapeutics, Inc. Announces Data Presentations at the Upcoming 59th American Society of Hematology Annual ... - GlobeNewswire (press release)
globenewswire.com - November 2 at 9:48 AM
TG Therapeutics, Inc. Announces Data Presentations at the Upcoming 59th American Society of Hematology Annual MeetingTG Therapeutics, Inc. Announces Data Presentations at the Upcoming 59th American Society of Hematology Annual Meeting
finance.yahoo.com - November 2 at 9:48 AM
TG Therapeutics, Inc. to Host Post ECTRIMS-ACTRIMS Conference Call to Review Data Presented on TG-1101 ... - GlobeNewswire (press release)TG Therapeutics, Inc. to Host Post ECTRIMS-ACTRIMS Conference Call to Review Data Presented on TG-1101 ... - GlobeNewswire (press release)
globenewswire.com - October 31 at 10:33 AM
TG Therapeutics, Inc. to Host Post ECTRIMS-ACTRIMS Conference Call to Review Data Presented on TG-1101 (ublituximab) in Multiple SclerosisTG Therapeutics, Inc. to Host Post ECTRIMS-ACTRIMS Conference Call to Review Data Presented on TG-1101 (ublituximab) in Multiple Sclerosis
finance.yahoo.com - October 31 at 10:32 AM
TG Therapeutics (TGTX) Reports Results from Ongoing Phase 2 ... - StreetInsider.comTG Therapeutics (TGTX) Reports Results from Ongoing Phase 2 ... - StreetInsider.com
www.streetinsider.com - October 27 at 9:25 PM
TG Therapeutics (TGTX) Reports Results from Ongoing Phase 2 Study of TG-1101 in Patients with MS at ECTRIMS - ACTRIMSTG Therapeutics (TGTX) Reports Results from Ongoing Phase 2 Study of TG-1101 in Patients with MS at ECTRIMS - ACTRIMS
www.streetinsider.com - October 27 at 4:20 PM
TG Therapeutics, Inc. Announces Additional Updated Results from the Ongoing Phase 2 Study of TG-1101 (ublituximab) in Patients with Multiple Sclerosis at the 7th Joint ECTRIMS – ACTRIMS MeetingTG Therapeutics, Inc. Announces Additional Updated Results from the Ongoing Phase 2 Study of TG-1101 (ublituximab) in Patients with Multiple Sclerosis at the 7th Joint ECTRIMS – ACTRIMS Meeting
finance.yahoo.com - October 27 at 4:20 PM
TG Therapeutics (TGTX) Announces Updated Results from Ongoing Phase 2 Study of TG-1101 in Patients with MS - StreetInsider.comTG Therapeutics (TGTX) Announces Updated Results from Ongoing Phase 2 Study of TG-1101 in Patients with MS - StreetInsider.com
www.streetinsider.com - October 26 at 11:47 AM
TG Therapeutics, Inc. Announces Updated Results from the Ongoing Phase 2 Study of TG-1101 (ublituximab) in Patients with Multiple Sclerosis at the 7th Joint ECTRIMS – ACTRIMS MeetingTG Therapeutics, Inc. Announces Updated Results from the Ongoing Phase 2 Study of TG-1101 (ublituximab) in Patients with Multiple Sclerosis at the 7th Joint ECTRIMS – ACTRIMS Meeting
finance.yahoo.com - October 26 at 11:47 AM
Commit To Buy TG Therapeutics At $5, Earn 21% Using OptionsCommit To Buy TG Therapeutics At $5, Earn 21% Using Options
www.thestreet.com - October 25 at 9:07 PM
TG Therapeutics (TGTX) versus Its Competitors Critical AnalysisTG Therapeutics (TGTX) versus Its Competitors Critical Analysis
www.americanbankingnews.com - October 25 at 4:26 AM
$40,000.00 in Sales Expected for TG Therapeutics, Inc. (TGTX) This Quarter$40,000.00 in Sales Expected for TG Therapeutics, Inc. (TGTX) This Quarter
www.americanbankingnews.com - October 22 at 5:30 AM
TG Therapeutics, Inc. (TGTX) Receives Average Recommendation of "Buy" from AnalystsTG Therapeutics, Inc. (TGTX) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - October 18 at 11:02 PM

SEC Filings

TG Therapeutics (NASDAQ:TGTX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

TG Therapeutics (NASDAQ:TGTX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

TG Therapeutics (NASDAQ TGTX) Stock Chart for Saturday, December, 16, 2017

Loading chart…

This page was last updated on 12/16/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.